ArticleNPJ breast cancer2026
Simultaneous inhibition of PARP/AKT to intercept nascent BRCA1/2
Lin Wang, Brian R Sardella, Emily K Aronson, Zhaoji Liu, Xiaohui Li, Gerburg M Wulf, Yujing J Heng
Abstract read
In one paragraphArticle in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Lin Wang *Department of Medicine, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA, USA.
Brian R Sardella *Department of Pathology, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA, USA.
Emily K Aronson *Department of Medicine, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA, USA.
Zhaoji LiuDepartment of Medicine, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA, USA.
Xiaohui LiDepartment of Medicine, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA, USA.
Gerburg M WulfDepartment of Medicine, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA, USA.
Yujing J HengDepartment of Pathology, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA, USA. yheng@bidmc.harvard.edu.
Funding
Optimization of PI3K-inhibitors to augment the efficacy of microtubule-disrupting chemotherapyR01CA226776 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WULF, GERBURG M · 2018 to 2022
$2.1MGender-affirming estrogen therapy and breast cancer treatment outcomeR21CA267088 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI HENG, YU JING JAN, WULF, GERBURG M · 2022 to 2023
$536kGender-Affirming Testosterone Therapy on Breast Cancer Risk and Treatment OutcomesR56CA284564 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI HENG, YU JING JAN, WULF, GERBURG M · 2023 to 2023
$300kBreast Cancer Research Foundation 25-177National Cancer Institute, United States R21CA267088NCI NIH HHS R01 CA226776NCI NIH HHS R01CA226776NCI NIH HHS R21 CA267088NCI NIH HHS R56CA284564
6 · The paper itselfAbstract
We utilized the K14-Cre Brca1
Identifiers
PMID41545354
PMCPMC12920871
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390